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A b s t r a c t
Right heart catheterisation (RHC) is the ‘gold standard’ for haemodynamic assessment of the pulmonary circulation. For the 
diagnosis of pulmonary hypertension (PH), the guidelines of the European Society of Cardiology require a mean pulmonary 
arterial pressure ≥ 25 mm Hg to be confirmed by direct haemodynamic measurement. Additionally, RHC provides a lot of 
valuable information about the differential diagnosis and severity of PH, and also helps determine the patient’s prognosis. Acute 
vasoreactivity testing performed in patients with pulmonary arterial hypertension is intended to identify the group of patients 
who should be treated with calcium channel blockers. Patients referred for heart transplantation require advanced pulmonary 
vascular disease to be ruled out either on resting examination or during vasoreactivity testing. RHC is a component of such 
interventional procedures as balloon atrial septostomy, closure of intracardiac shunts in congenital heart and great vessel defects, 
valvuloplasty for pulmonary valve stenosis, and pulmonary angioplasty. Pulmonary angiography is an examination recom-
mended when selecting patients for pulmonary endarterectomy or balloon pulmonary angioplasty in thromboembolic PH. 
Due to the dynamic growth in the number of patients diagnosed with and treated for PH in Poland, the Boards of the Polish 
Cardiac Society’s Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions have undertaken 
a joint project to develop recommendations to standardise guidelines for RHC procedure, acute vasoreactivity testing and 
pulmonary angiography at cardiac wards and haemodynamic laboratories in Poland. This document has been prepared by 
experts delegated by the Working Group on Pulmonary Circulation and the Association of Cardiovascular Interventions, and 
subsequently approved by the Boards of both organs of the Polish Cardiac Society.
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INTRODUCTION
Right heart catheterisation (RHC) remains an essential exami-
nation to diagnose pulmonary hypertension (PH), to assess the 
patient’s prognosis, and to select patients for procedural treat-
ment of PH, congenital heart defects and heart transplanta-
tion [1]. Due to the dynamic growth in the number of patients 
diagnosed with and treated for PH in Poland, experts from 
the Polish Cardiac Society’s Working Group on Pulmonary 
Circulation and Association of Cardiovascular Interventions 
have undertaken a joint project to develop recommenda-
tions to standardise guidelines for RHC procedure, acute 
vasoreactivity testing (AVT) and pulmonary angiography at 
cardiac wards and haemodynamic laboratories in Poland. The 
complete guidelines are presented in a separate publication 
[1]. What follows is a summary of the key recommendations.
RIGHT HEART CATHETERISATION
The usefulness of RHC depends on the aetiology of PH [2, 3]. 
Nevertheless, it is an examination which should be performed 
in order to confirm the diagnosis of PH. RHC should be pre-
ceded by echocardiography with an estimate of the likelihood 
of PH. No pulmonary arterial hypertension (PAH)-specific drug 
therapy should be initiated until PH is confirmed by RHC. 
Control RHC should be performed in patients with PAH in the 
case of clinical aggravation, after causes other than progression 
of PAH have been ruled out, in order to consider modifying 
the patient’s current therapy.
It is recommended that RHC be performed in a haemo-
dynamic laboratory, in a hybrid operating room equipped with 
an angiocardiograph, or in another room equipped with X-ray 
fluoroscopy, a device for invasive measurements of blood 
pressure, and cardiopulmonary resuscitation equipment. 
During the procedure, the patient should be continuously 
monitored for cardiovascular and respiratory disorders. Prior 
to the procedure, the patient should be fasted for at least 
4–6 h. Physical examination and medical interview should 
be performed, and the patient’s informed consent to the 
procedure should be obtained in writing. While zeroing to 
atmospheric pressure, transducers should be positioned at 
the mid-chest level. RHC procedures are normally performed 
under local anaesthesia, most often with lidocaine 2%. Usu-
ally, central venous access is used, obtained via the internal 
jugular, subclavian, or femoral vein. Access through the basilic 
vein is chosen less frequently. Access via the right internal 
jugular vein is the easiest way to insert a Swan-Ganz catheter 
into the pulmonary artery. RHC catheter insertion via the 
femoral access can be more difficult than via the veins of the 
upper part of the body, although the former approach may 
be preferred in patients at a higher risk of haemorrhagic com-
plications. Before obtaining vascular access, ultrasound may 
be performed to confirm the location of the vein. Pressures 
in the cardiac chambers are measured during free breathing, 
while the value of pulmonary artery wedge pressure (PAWP) 
should be measured at the end of expiration. Normally cardiac 
output (CO) is measured by thermodilution. If three consecu-
tive measurements of CO do not differ by more than 10%, the 
measurements can be considered reliable. We suggest using 
the mean value from the last three measurements as the final 
result of the CO measurement. Oximetry measurements in 
the superior vena cava and pulmonary artery during the first 
RHC in the patient with PAH can be considered in order to 
detect any left-to-right shunt.
In the presence of cardiac shunt defects, CO should 
be measured by the Fick method. It is also possible to es-
timate oxygen consumption on the basis of the patient’s 
age, gender and body surface area according to the formula 
proposed by Bergsta [4], or on the basis of body surface 
area (BSA × 125 mL/min or BSA × 110 mL/min in elderly 
patients) [5]. For quantification of intracardiac shunt volume, 
the pulmonary (Qp) to systemic flow (Qs) ratio should be 
calculated in order to select patients for treatment. According 
to current guidelines, a pulmonary to systemic flow ratio of 
more than 1.5 indicates the presence of a significant shunt. 
In patients with cardiac shunt defects, it is recommended that 
a complete oximetry run be performed. Angiocardiography 
can be of decisive importance in the case of ambiguous results 
of non-invasive examinations to either confirm or exclude the 
presence of a shunt between cardiac chambers or vascular 
fistulae in the pulmonary circulation. Contrast-enhanced 
angiocardiography is not routinely used in adults. However, 
it is a very good method for visualising extracardiac shunts 
such as pulmonary arteriovenous fistulae.
After the procedure, the patient should routinely remain 
in a semisupine position for 2–3 h with light compression 
applied to the vascular access site.
Contraindications to RHC
Contraindications to RHC include:
 — severe haemorrhagic diathesis;
 — anticoagulant therapy with International Normalisation 
Ratio > 2 (relative contraindication);
 — uncorrected electrolyte disturbances (hypo- or hyper-
kalaemia);
 — when non-invasive examinations may be performed as 
a substitute for RHC;
 — severe ventricular and supraventricular arrhythmias;
 — advanced and complete atrioventricular block;
 — caution should be exercised in patients with left bundle 
branch block, as complete heart block is a possible oc-
currence.
Normal haemodynamic parameters of  
the pulmonary circulation
Normal haemodynamic parameters of the pulmonary circula-
tion are shown in Table 1. According to the current definition, 
PH is considered a condition with a mean pulmonary arterial 
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pressure (mPAP) of at least 25 mm Hg. In the population of 
patients with systolic or diastolic left ventricular (LV) dysfunc-
tion revealed by echocardiography, and with risk factors of 
heart failure with preserved LV systolic function, in the case 
of a PAWP ≤ 15 mm Hg we suggest supplementing cardiac 
catheterisation by direct measurement of LV end-diastolic 
pressure [6]. Observing the effect of intravenous administra-
tion of 500 mL NaCl 0.9% over 5–10 min on the PAWP value 
can also be considered [7]. There is no sufficiently docu-
mented data to define the limit of pressure in the pulmonary 
artery which would allow the diagnosis of PH on exercise.
Complications associated with  
pulmonary artery catheterisation
Complications of RHC can be classified into those related to 
vascular access, those related to catheter manipulation when 
advancing it through the cardiac chambers, and those related 
to catheter placement in the pulmonary bed. 
In 2006, Hoeper et al. [8] published results of a study 
on the risk of complications associated with planned RHC, 
pressure measurements and vasoreactivity testing in patients 
with PH of various aetiologies. The study analysed 7,218 RHC 
procedures. Death occurred in four (0.055%) patients, but only 
in two cases was it directly related to the procedure (rupture 
of the pulmonary artery when measuring wedge pressure and 
bleeding into the lungs after pulmonary angiography). The inci-
dence of all adverse events in the study population was 1.1%. 
38% of complications were related to venous access, 29% to 
the catheterisation itself, and 20% to AVT. Types and incidence 
of complications associated with RHC are shown in Table 2.
PULMONARY VASOREACTIVITY TESTING
AVT is a diagnostic procedure used to assess the preserved 
ability of the pulmonary arterial bed to vasodilate under the 
action of substances considered to be referential.
AVT performed in patients with PAH is used to predict 
a beneficial effect of calcium channel blocker therapy [9]. 
AVT of the pulmonary arteries should be performed in every 
patient with idiopathic or familial PAH prior to the initiation of 
therapy [10]. AVT of the pulmonary arteries can be considered 
in patients with other types of PAH. However, the likelihood 
of a positive response to the test and long-term benefits of 
calcium channel blocker therapy is low.
A positive acute response in patients with PAH is defined 
as a decrease in mPAP of at least 10 mm Hg to reach a value 
below 40 mm Hg, with no significant decrease in CO [11].
The substance of first choice for AVT of the pulmonary 
arteries in PAH appears to be nitric oxide (NO). It is ad-
ministered in the respiratory mixture, at a concentration of 
10–20 ppm for 5 min [2].
Vasoreactivity testing may be also performed using:
 — iloprost nebulised via a dedicated nebuliser at a dose 
of 5 µg measured in the mouthpiece; haemodynamic 
measurements should be performed within 15 min after 
the beginning of nebulisation [12, 13];
Table 1. Normal haemodynamic parameters of the pulmonary 
circulation
Parameter Value (range)
Pressure: pulmonary artery
Systolic
Mean
Diastolic
15–30 mm Hg
8–20 mm Hg
3–12 mm Hg
Right atrium, mean 0–8 mm Hg
Left atrium, mean 2–12 mm Hg
Pulmonary artery wedge pressure 4–15 mm Hg
Left ventricular end-diastolic pressure 5–12 mm Hg
Cardiac output 4–8 L/min
Cardiac index 2.5–4.2 L/min/m2
Pulmonary vascular resistance < 2.5 WU
Total pulmonary resistance < 3.5 WU
Pulmonary vascular resistance index < 3.0 WU
Systemic vascular resistance 10–20 WU
Oxygen saturation of blood in  
the pulmonary trunk
70–80%
Table 2. Types and incidence of complications associated with 
right heart catheterisation [8]
Types and incidence of complications Incidence [%]
Central venous access-related
Accidental puncture of an artery ≤ 3.6
Haematoma 5.3
Neuropathy 0.1–1.1
Pneumothorax 0.3–1.9
Air embolism 0.5
Catheterisation-related
Benign arrhythmias > 20
Malignant arrhythmias 0.3–3.8
Mild worsening of tricuspid regurgitation 17
Right bundle branch block 0.1–4.3
Complete heart block (in the initial presence 
of left bundle branch block)
0–8.5
Venous thrombosis 0.5–3
Catheter-related
Pulmonary artery rupture 0.03–0.7
Infectious complications — sepsis 0.7–3.0
Infective endocarditis 2.2–7.1
Pulmonary infarction 0.1–2.6
Intramural haematoma 28–61
Death 0.02–1.5
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 — adenosine administered in continuous intravenous infu-
sion at an initial dose of 50 µg/kg BW/min, titrated by 
50 µg at 2-min intervals to a maximum dose of 350 µg/kg 
BW/min or to the maximum tolerated dose [2];
 — epoprostenol administered in intravenous infusion at an 
initial dose of 2 ng/kg BW/min, titrated by 2 ng/kg BW/min at 
10-min intervals to a maximum dose of 10 ng/kg BW/min [2].
Calcium channel blocker treatment is contraindicated in 
patients without prior confirmation of preserved reactivity of 
the pulmonary arterial bed.
In the group of patients with cardiac shunt defects, 
a baseline pulmonary vascular resistance index (PVRI) 
< 6 Wood units (WU)/m2 and a ratio of pulmonary vascu-
lar resistance (PVR) to systemic vascular resistance (SVR) 
(PVR/SVR < 0.3) is considered indicative of a favourable 
outcome immediately following surgery. A positive outcome 
is also observed in patients with a PVRI of between 6 and 
9 WU/m2 and/or a PVR/SVR > 0.3–0.5. However, these values 
decrease during NO inhalation at a low or moderate concen-
tration (20–40 ppm) by at least 20% and below the lower 
limits of these ranges. If the baseline PVRI is > 9 WU/m2 or 
the PVR/SVR is > 0.5, then the risk of perioperative compli-
cations is significant [14, 15] even when the reactivity criteria 
are met. Correction of a congenital shunt defect can be per-
formed without additional haemodynamic tests in patients 
with a PVRI < 4 WU/m2 or a PVR < 2.3 WU. If the PVRI 
is > 8 WU/m2 or the PVR is > 4.6 WU, the shunt should not 
be corrected. In the setting of intermediate values, AVT of 
the pulmonary arteries or the balloon occlusion test can be 
considered. Based on the current data, no preferable method-
ology of these tests or criteria for a positive test result can be 
recommended. The authors of the document recommend that, 
until data from long-term randomised studies in patients with 
PH due to congenital heart diseases is published, drugs and 
their methods of administration recommended for the diag-
nostics of idiopathic PAH should be used [16]. Shunt closure is 
contraindicated in patients with Eisenmenger syndrome [17].
When selecting patients for heart transplantation, 
RHC and AVT are the standard procedures. A PVR > 5 WU, 
a PVRI > 6 WU/m2 and a transpulmonary pressure gradi-
ent (TPG) > 16 mm Hg is considered a contraindication for 
transplantation due to a very high risk of early post-transplant 
mortality caused by right ventricular failure. According to the 
International Society for Heart and Lung Transplantation, AVT 
should be performed when the PVR is > 3 WU, TPG > 15 mm 
Hg, systolic PAP > 50 mm Hg, and systemic systolic arterial 
pressure not lower than 85 mm Hg [9]. Nevertheless, it is 
worth performing AVT at earlier stages of PH — when the 
PVR is > 2.5 WU, and TPG > 12 mm Hg [18]. If during 
AVT, previously increased PVR decreases to < 2.5 WU, heart 
transplantation becomes possible provided that that is not ac-
companied by a fall in systemic blood pressure < 85 mm Hg. If 
the decrease in the PVR is accompanied by systemic hypoten-
sion, the patient still remains at risk of early post-operative right 
ventricular failure and increased perioperative mortality [19]. 
The definition of pulmonary vasoreactivity and reversibility of 
PH in heart transplant candidates differs from that in the case 
of PAH. In orthotopic heart transplantation (OHT) candidates, 
PH is considered reversible if in AVT with one of the aforemen-
tioned substances a PVR < 2.5–3 WU and a TPG < 12 mm Hg 
is achieved, with no fall in systemic systolic arterial pressure 
below 85 mm Hg as assessed by direct measurement. Sodium 
nitroprusside (SNP) is administered via an infusion pump at 
specific doses and time intervals (Table 3) to reduce initially 
increased PVR and TPG values, without reducing systemic 
systolic pressure below 85 mm Hg. The prognostic value of 
AVT with SNP in OHT candidates has been confirmed by 
Costard-Jackle and Fowler [20].
In AVT prior to OHT, also NO [21–23], sildenafil [24, 25], 
iloprost and milrinone may be used.
PULMONARY ANGIOGRAPHY
Pulmonary angiography is the ‘gold standard’ in the diag-
nostics of chronic thromboembolic pulmonary hypertension 
(CTEPH). It should be performed in patients with ambigu-
ous results of non-invasive imaging examinations, as well 
as in candidates for procedural treatment of CTEPH (i.e. 
pulmonary endarterectomy or percutaneous pulmonary 
angioplasty) [26]. Pulmonary angiography should be per-
formed after haemodynamic assessment of the pulmonary 
circulation and from the same vascular access as in RHC. 
The most common catheter used for angiography is the pig-
tail catheter. Contrast agent is selectively administered into 
the right and left pulmonary artery via an automatic pump 
under a maximum pressure of 600–900 psi. For a single 
administration, 30–50 mL of contrast agent given at a rate 
of 10–25 mL/s is usually used. Advanced right heart failure 
requires the administration of a smaller volume of contrast 
agent at a lower flow rate. It is recommended that the right 
and the left pulmonary artery be selectively visualised in at 
least two projections using a large-field image intensifier 
and with the use of nonionic and low-osmolar contrast 
Table 3. Dosage of sodium nitroprusside (SNP) and duration 
of each stage of acute vasoreactivity testing when selecting 
patients for orthotopic heart transplantation 
Dose of SNP Duration of administration
0.25 µg/kg BW/min 3–5 min
0.5 µg/kg BW/min 3–5 min
1.0 µg/kg BW/min 3–5 min
1.5 µg/kg BW/min 3–5 min
2.0 µg/kg BW/min 3–5 min
2.5 µg/kg BW/min 3–5 min
3.0 µg/kg BW/min 3–5 min
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agents. Two projections are normally obtained for each 
lung: posterior-anterior and lateral or oblique (45 degrees) 
[27]. In order to reduce contrast volume, subtraction angio-
graphy may be performed. Pulmonary angiography can be 
performed relatively safely even in patients with severe PH 
and right ventricular failure [28] provided that standard 
recommendations are followed and the operator is appro-
priately experienced. Classic angiographic lesions indicating 
CTEPH include pouch defects, webs and bands, luminal ir-
regularities and abrupt vessel narrowing, as well as occlusion 
of the artery at its orifice [29]. Pulmonary artery obstruction 
or occlusion is usually accompanied by a decrease in, or lack 
of, pulmonary parenchymal perfusion. When described, seg-
mental pulmonary arteries should be numbered according 
to the pulmonary segments that they vascularise. Given that 
angiographic results are the primary criterion for operability 
of CTEPH, imaging should be optimised.
However, as it is an invasive examination with a risk of 
complications, classic pulmonary angiography is rarely used 
in the diagnostics of acute pulmonary embolism [30]. The 
protocol for angiography in acute pulmonary embolism in-
volves selective administration of contrast agent (30–50 mL) 
into the right and left pulmonary artery by an automatic injec-
tor (15–25 mL/s). The diagnostic criteria for acute pulmonary 
embolism at pulmonary angiography include contrast filling 
defects or amputation of the pulmonary artery, which are 
indicative of a thrombus. In patients with high-risk pulmonary 
embolism, pulmonary angiography may precede percutane-
ous pulmonary embolectomy. After pulmonary angiography, 
the patient should be monitored for at least 24 h.
FORMAL REQUIREMENTS, CERTIFICATION OF 
PHYSICIANS AND RHC LABORATORIES
Currently, there are no precise recommendations for the 
number of RHC procedures needed to obtain and maintain 
their adequate quality [31–34].
To ensure the quality of RHC procedures and their maxi-
mum standardisation, the authors of these guidelines have 
decided to develop training requirements for RHT special-
ists. The training is completed with the title of Certified Right 
Heart Catheterisation Specialist.
Requirements for the Right Heart  
Catheterisation Certificate  
(Right Heart Catheterisation Specialist — RHCS)
1. The RHCS Certificate can be obtained by an internist, 
a cardiologist (including paediatric cardiologist), a cardiac 
surgeon, an anaesthesiologist or a resident (after at least 
two years of residency) trained in one of the aforemen-
tioned specialties, who is a member of the Association of 
Cardiovascular Interventions of the Polish Cardiac Society 
or the Working Group on Pulmonary Circulation of the 
Polish Cardiac Society.
2. The training should be conducted under the supervision 
of the Head of the Certified Right Heart Catheterisation 
Laboratory and/or a person who has already obtained 
the title of RHCS.
3. In order to obtain the title of RHCS, a physician has to inde-
pendently perform and interpret at least 75 examinations.
4. The examinations performed should be documented in 
the database of the Association of Cardiovascular Inter-
ventions of the Polish Cardiac Society or in a procedure 
log book (if the Laboratory does not have access to the 
database of the Association of Cardiovascular Interven-
tions).
5. During the training, the trainee is required to undergo 
a course at the Certified Laboratory. It is also recom-
mended for an internship to be completed at a centre 
performing AVT to select patients for heart transplanta-
tion, and with accreditation for transplant procedures.
6. An application for the certificate is to be submitted by 
the head of the laboratory or the training supervisor. 
The application shall be accompanied by a declaration 
confirming the number of procedures performed and 
confirming completion of the training.
7. The certificate is signed by the Chairman of the Working 
Group on Pulmonary Circulation and by the Chairman 
of the Association of Cardiovascular Interventions of the 
Polish Cardiac Society.
Requirements for the accreditation of Right  
Heart Catheterisation Referral Laboratories
1. Having accreditation (a certificate) as a RHC Referral 
Laboratory confirms the high quality of the procedures 
performed, and ensures patient safety and the repeat-
ability of results of catheterisation performed according 
to the established and described standards.
2. RHC Referral Laboratory Certificates are issued by the 
Executive Board of the Polish Cardiac Society at the re-
quest of the Board of the Working Group on Pulmonary 
Circulation and/or by the Board of the Association of 
Cardiovascular Interventions.
3. An application is to be submitted by the Head of the 
Laboratory, together with an enclosed declaration of 
compliance with relevant criteria, and with other docu-
ments as set forth in these requirements.
Equipment:
 — Angiocardiograph with digital image recording
 — Polyphysiograph (enabling measurement of pressures 
and ECG recording)
 — Pulse oximeter
 — Defibrillator, resuscitation equipment
 — External or endocavitary cardiac stimulator
 — Device for the administration of drugs used in acute 
haemodynamic testing (NO or iloprost, or SNP)
 — Device for measuring arterial blood gases at the location
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Procedures:
 — At least 50 RHC procedures per year, including at least 
20 with acute reversibility testing
 — Participation in non-commercial scientific programmes 
on PH
Personnel:
 — At least two operators, including at least one with the 
RHCS certificate
Conflict of interest: none declared
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